HIVEP2 Up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with HIVEP2 Up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with HIVEP2 Up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with HIVEP2 Up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with HIVEP2 Up.

Results found

Linked to

 

Label

Description

 

Gene

ENSG00000131100 - ATPase H+ transporting V1 subunit E1

Gene

ENSG00000143536 - cornulin

Gene

ENSG00000092295 - transglutaminase 1

Gene

ENSG00000130703 - oxysterol binding protein like 2

Gene

ENSG00000112335 - sorting nexin 3

Gene

ENSG00000137947 - general transcription factor IIB

Gene

ENSG00000137817 - poly(ADP-ribose) polymerase family member 6

Gene

ENSG00000142319 - solute carrier family 6 member 3

Gene

ENSG00000102970 - C-C motif chemokine ligand 17

  • Gene

    ENSG00000131100 - ATPase H+ transporting V1 subunit E1


  • Gene

    ENSG00000143536 - cornulin


  • Gene

    ENSG00000092295 - transglutaminase 1


  • Gene

    ENSG00000130703 - oxysterol binding protein like 2


  • Gene

    ENSG00000112335 - sorting nexin 3


  • Gene

    ENSG00000137947 - general transcription factor IIB


  • Gene

    ENSG00000137817 - poly(ADP-ribose) polymerase family member 6


  • Gene

    ENSG00000142319 - solute carrier family 6 member 3


  • Gene

    ENSG00000102970 - C-C motif chemokine ligand 17

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.